低分子肝素治疗急性脑梗死的疗效和安全性的临床试验  

The Safety and Efficacy of Fraxiparine in the Treatment of Acute Cerebral Infarction

作　　者：徐恩[1] 陆雪芬[1] 

机构地区：[1]广州医学院第二附属医院神经科学研究所,广州510260

出　　处：《中国医药导刊》2003年第3期210-212,共3页Chinese Journal of Medicinal Guide

摘　　要：目的:探讨低分子量肝素治疗急性脑梗死的疗效和安全性。方法:对170例急性脑梗死患者以低分子量肝素(速碧林)0.4-0.6ml皮下注射,2次/日,疗程(10±2)d。结果:治疗前后ESS和ADL积分均有显著差异;梗死灶面积较大者的ESS积分增加率显著高于梗死灶面积较小者;治疗时间越早,疗效相对也提高。治愈31例(18.23％),基本治愈22例(12.94％),显效39例(22.94％),总有效率75.88％。2例全身轻度出血(1.2％),1例症状性脑出血(0.6％),部分病人有一过性谷丙转氨酶增高。结论:低分子肝素治疗急性脑梗死安全、有效。Objective: To evaluate the safety and efficacy of Fraxiparine in the treatment of acute cerebral infarction. Methods: 170 patients were treated with 0.4-0.6ml Fraxiparine subcutaneous injection, bid×(10±2)d. Results: The ESS scores and ADL scores were significantly increased after treatment. The rate of relatively increased ESS scores in large infarct foci was markedly higher than that in small foci. The earlier the treatment, the better the effect will be. 31 cases fully recovered (18.23%), 22 cases almost recovered (12.94%), 39 cases achieved remarkable progress (22.94%); the effective rate came to 75.88%. The mild systemic hemorrhage occurred in 2 cases (1.2%), symptomatic cerebral hemorrhage occurred in 1 case (0.6%). SGPT increased transiently in some patients. Conclusion: This study revealed that Fraxiparine was efficacious and relatively safe in treatment of acute cerebral infarctions.

关 键 词：药物临床研究 低分子肝素 治疗 急性脑梗死 疗效 安全性 谷丙转氨酶 

分 类 号：R743.3[医药卫生—神经病学与精神病学]